Price
Financials
Consolidated, Rs crore| Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 5.28 | 4.76 | 5.38 | 4.31 | 2.82 | 3.45 | 6.18 | 3.55 | 1.03 | 0.33 | 0.30 | 1.51 |
| Expenses | 3.50 | 2.58 | 3.89 | 2.33 | 3.37 | 5.30 | 4.12 | 4.30 | 1.42 | 2.01 | 0.67 | 0.13 |
| Operating Profit | 1.78 | 2.18 | 1.49 | 1.98 | -0.55 | -1.85 | 2.06 | -0.75 | -0.39 | -1.68 | -0.37 | 1.38 |
| OPM % | 33.71% | 45.80% | 27.70% | 45.94% | -19.50% | -53.62% | 33.33% | -21.13% | -37.86% | -509.09% | -123.33% | 91.39% |
| Other Income | 0.00 | 0.03 | 0.02 | 0.40 | 0.01 | 0.68 | 0.03 | 0.08 | 0.04 | 0.04 | 0.00 | 0.16 |
| Interest | 1.01 | 1.13 | 1.14 | 1.20 | 2.48 | 3.40 | 2.85 | 2.90 | 2.14 | -0.06 | 0.88 | -0.11 |
| Depreciation | 0.61 | 0.65 | 0.66 | 0.66 | 1.31 | 1.36 | 1.54 | 2.95 | 1.69 | -0.17 | 0.61 | -0.23 |
| Profit before tax | 0.16 | 0.43 | -0.29 | 0.52 | -4.33 | -5.93 | -2.30 | -6.52 | -4.18 | -1.41 | -1.86 | 1.88 |
| Tax % | 68.75% | 9.30% | -106.90% | 13.46% | 2.08% | 1.52% | -0.87% | -3.07% | -1.20% | -2.13% | -2.69% | -2.66% |
| Net Profit | 0.06 | 0.39 | 0.02 | 0.07 | -2.56 | -3.92 | -0.54 | -1.78 | -2.07 | -1.37 | -1.82 | 1.93 |
| EPS in Rs | 0.10 | 0.62 | 0.03 | 0.11 | -4.06 | -6.21 | -0.86 | -2.82 | -3.28 | -2.17 | -2.56 | 2.71 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales | 12.08 | 13.75 | 9.82 | 9.40 | 5.83 | 9.72 | 1.96 | 1.82 |
| Expenses | 8.81 | 9.38 | 5.87 | 5.93 | 8.22 | 8.41 | 6.21 | 0.80 |
| Operating Profit | 3.27 | 4.37 | 3.95 | 3.47 | -2.39 | 1.31 | -4.25 | 1.02 |
| OPM % | 27.07% | 31.78% | 40.22% | 36.91% | -40.99% | 13.48% | -216.84% | 56.04% |
| Other Income | 0.23 | 0.11 | 0.03 | 0.42 | 0.69 | 0.11 | 0.11 | 0.16 |
| Interest | 1.69 | 1.95 | 2.14 | 2.35 | 5.89 | 5.75 | 4.07 | 0.78 |
| Depreciation | 0.71 | 1.19 | 1.25 | 1.32 | 2.67 | 4.50 | 4.42 | 0.39 |
| Profit before tax | 1.10 | 1.34 | 0.59 | 0.22 | -10.26 | -8.83 | -12.63 | 0.01 |
| Tax % | 36.36% | 24.63% | 23.73% | 40.91% | 1.75% | -2.49% | 5.23% | -900.00% |
| Net Profit | 0.70 | 1.01 | 0.45 | 0.14 | -10.44 | -8.61 | -13.29 | 0.11 |
| EPS in Rs | 1.11 | 1.58 | 0.71 | 0.14 | -10.27 | -3.68 | -7.56 | 0.15 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | -29% | -32% | -7% | ||
| Compounded Profit Growth | % | -24% | 26% | 102% | ||
| Stock Price CAGR | % | -31% | -22% | -15% | ||
| Return on Equity | % | -15% | -16% | 1% |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6.31 | 6.31 | 6.31 | 6.31 | 6.31 | 6.31 | 6.31 | 7.11 |
| Reserves | 15.94 | 17.16 | 17.61 | 17.70 | 11.20 | 8.89 | 4.11 | 14.06 |
| Borrowings | 13.25 | 17.37 | 35.97 | 44.86 | 57.16 | 60.96 | 70.09 | 38.08 |
| Other Liabilities | 3.51 | 7.74 | 9.74 | 12.53 | 10.04 | 9.24 | 5.37 | 6.85 |
| Total Liabilities | 39.01 | 48.58 | 69.63 | 81.40 | 84.71 | 85.40 | 85.88 | 66.10 |
| Fixed Assets | 17.90 | 20.76 | 29.39 | 36.12 | 57.22 | 54.15 | 55.50 | 48.08 |
| CWIP | 3.70 | 7.00 | 19.34 | 28.47 | 10.60 | 12.53 | 13.47 | 0.00 |
| Investments | 1.95 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00 |
| Other Assets | 15.46 | 20.82 | 20.90 | 16.81 | 16.89 | 18.72 | 16.91 | 15.02 |
| Total Assets | 39.01 | 48.58 | 69.63 | 81.40 | 84.71 | 85.40 | 85.88 | 66.10 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | -1.04 | 2.34 | 6.97 | 5.28 | -0.63 | 2.68 | -2.41 | -5.22 |
| Cash from Investing Activity | -5.73 | -7.59 | -22.30 | -17.24 | -5.91 | -3.31 | -6.69 | -6.87 |
| Cash from Financing Activity | 9.94 | 2.17 | 17.78 | 9.53 | 6.41 | 0.69 | 9.16 | 12.08 |
| Net Cash Flow | 3.18 | -3.07 | 2.46 | -2.43 | -0.13 | 0.06 | 0.06 | -0.01 |
| Free Cash Flow | -3.52 | -5.01 | -15.23 | -11.90 | -6.54 | -0.63 | -9.10 | -12.09 |
| CFO/OP | -32% | 54% | 176% | 152% | 26% | 205% | 57% | -512% |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 47.14 | 36.90 | 74.71 | 43.88 | 122.71 | 117.91 | 465.56 | 513.41 |
| Inventory Days | 2,400.15 | |||||||
| Days Payable | 1,821.31 | |||||||
| Cash Conversion Cycle | 47.14 | 36.90 | 74.71 | 43.88 | 122.71 | 117.91 | 1,044.40 | 513.41 |
| Working Capital Days | 260.76 | 259.61 | 91.06 | -135.13 | -163.40 | -217.42 | -2,126.68 | 435.19 |
| ROCE % | 8.35% | 5.21% | 3.77% | -5.82% | -4.16% | -11.58% | 1.19% |
| Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | May 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 69.11% | 69.00% | 69.00% | 69.36% | 69.36% | 69.36% | 69.36% | 69.36% | 69.36% | 72.81% | 72.81% | 72.81% |
| Public | 30.89% | 31.00% | 31.00% | 30.64% | 30.65% | 30.64% | 30.64% | 30.64% | 30.64% | 27.18% | 27.19% | 27.18% |
| No. of Shareholders | 361 | 412 | 409 | 393 | 394 | 388 | 418 | 424 | 408 | 408 | 419 | 426 |
Fundamentals
Market Cap₹ 14.6 Cr.
Current Price₹ 20.5
Stock P/E133
Book Value₹ 29.8
ROCE1.19 %
ROE0.70 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)-7%
Compounded Profit Growth (TTM)102%
Consolidated figures.
Valuation
Market capRs 14 Cr
Enterprise valueRs 74 Cr
Price to book0.89x
Price to sales1.40x
EV / EBITDA52.37x
EV / sales7.65x
Price to cash flow5.06x
Earnings yield-17.10%
P/E, 3-year average770.41x
P/B, 3-year average2.54x
P/E, 5-year average352.16x
P/B, 5-year average2.87x
Profitability
Operating margin (excl. other income)13.48%
Operating margin (incl. other income)14.61%
EBITDA margin14.61%
Pre-tax margin-90.84%
Net profit margin-23.87%
ROE-14.19%
ROCE-4.08%
ROA-2.73%
ROE, 3-year average-15.01%
ROCE, 3-year average-2.06%
ROA, 3-year average-3.47%
ROE, 5-year average-7.75%
ROCE, 5-year average1.57%
ROA, 5-year average-1.47%
ROIC (approx.)-3.95%
Tax rate2.49%
Other income / net worth0.72%
Growth
Sales growth (latest year)66.72%
Sales CAGR, 3 years-0.34%
Sales CAGR, 5 years-4.25%
Per share
EPS (TTM)Rs -3.68
EPS (latest year)Rs -3.68
EPS, 3-year averageRs -4.60
EPS, 5-year averageRs -2.30
Book value per shareRs 24.08
Sales per shareRs 15.40
Cash flow per shareRs 4.25
Free cash flow per shareRs -19.15
Efficiency
Asset turnover0.11x
Fixed asset turnover0.18x
Inventory turnover0.26x
Inventory days1386 days
Debtor days118 days
Debtors turnover3.10x
Creditor days1821 days
Cash conversion cycle513 days
Working capital days435 days
Leverage
Total debtRs 61 Cr
Cash and bankRs 0 Cr
Net debtRs 61 Cr
Debt to equity4.01x
Net debt / EBITDA42.82x
Interest coverage-0.54x
Owners' fund to total sources17.80%
Debt to assets71.38%
Cash flow
Cash from Operating Activity (latest year)Rs 3 Cr
Cash from Investing Activity (latest year)Rs -3 Cr
Cash from Financing Activity (latest year)Rs 1 Cr
Net Cash Flow (latest year)Rs 0 Cr
Free cash flow (latest year)Rs -12 Cr
FCFE (approx.: FCF + change in debt)Rs -8 Cr
Sales to cash flow3.63x
Statement figures
Net sales (TTM)Rs 10 Cr
Net sales (latest year)Rs 10 Cr
Operating profit excl. other income (latest year)Rs 1 Cr
Other income (TTM)Rs 0 Cr
EBITDA (TTM)Rs 1 Cr
PBDT (TTM)Rs -4 Cr
Profit before tax (TTM)Rs -9 Cr
Tax (latest year)Rs -0 Cr
Net profit (TTM)Rs -2 Cr
Net profit (latest year)Rs -2 Cr
Depreciation (TTM)Rs 4 Cr
Interest (TTM)Rs 6 Cr
Cost of goods sold (latest year)Rs 2 Cr
Total expenditure (latest year)Rs 8 Cr
Total income (latest year)Rs 10 Cr
Share capitalRs 6 Cr
ReservesRs 9 Cr
Shareholders' fundsRs 15 Cr
Total assetsRs 85 Cr
Net blockRs 54 Cr
Capital work in progressRs 13 Cr
ReceivablesRs 3 Cr
InventoryRs 8 Cr
Other liabilitiesRs 9 Cr
Shares outstanding (crore)0.63
Ownership
Promoter holding72.81% (+3.45 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/B 0.89 is at the 23th percentile (median 1.35).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | 540729 | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | +4.4% | -2.8% | +7.2 pts |
| 1 month | -8.9% | -6.8% | -2.1 pts |
| 3 years | -51.2% | +14.2% | -65.3 pts |
| 5 years | -84.5% | +27.9% | -112.4 pts |
Red flags
F-score 6 of 8| look | Repeated losses Net loss in each of the last two years |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Mar 2026Sales ₹2 Cr -57.5% vs Mar 2024.
Net profit ₹2 Cr +208.4%.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Syngene International Ltd | 14,823 | 50.0 | 9.99 % |
| Indegene Ltd | 14,580 | 35.0 | 18.8 % |
| Suven Life Sciences Ltd | 9,176 | -79.5 % | |
| Vimta Labs Ltd | 2,642 | 32.7 | 25.2 % |
| Fabtech Technologies Ltd | 661 | 13.6 | 13.6 % |
| Bilcare Ltd | 229 | 11.5 | 7.06 % |
| Take Ltd | 208 | 35.2 | 18.5 % |
| Novelix Pharmaceuticals Ltd | 199 | 55.1 | 10.9 % |
| Jeevan Scientific Technology Ltd | 163 | 46.7 | 5.01 % |
| Adeshwar Meditex Ltd | 24 | 19.4 | 5.21 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Vanta Bioscience Ltd?
Vanta Bioscience Ltd (540729) has a market capitalisation of Rs 14.6 Cr. at the 2026-10-01 close.
What is the P/E ratio of Vanta Bioscience Ltd?
Vanta Bioscience Ltd trades at a P/E of 133 on trailing twelve-month profit, at the 2026-10-01 close.
What were Vanta Bioscience Ltd's latest quarterly results?
In the Mar 2026 quarter, Vanta Bioscience Ltd sales was Rs 2 Cr (-57.5% vs Mar 2024) and net profit was Rs 2 Cr.